产品
编 号：F015199
分子式：C51H69N13O11S2
分子量：1104.3
分子式：C51H69N13O11S2
分子量：1104.3
产品类型
规格
价格
是否有货
结构图
CAS No: 103429-32-9
产品详情
生物活性：
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.
体内研究：
CTAP (0-1 mg/kg, IP, single) blocks morphine’s antinociceptive effect.CTAP (10 mg/kg; IP, single) has no effect on L-DOPA-induced limb, axial, orolingual, or locomotor abnormal involuntary movements.CTAP is stable in the blood and serum of rats (T1/2 > 500 min), showing that the structure of this peptide offers enzymatic resistance. CTAP is extensively protein-bound to albumin in the perfusion medium (68.2%) and to proteins in rat serum (84.2%).Animal Model:Male Sprague-Dawley rats
Dosage:0, 0.1, 0.5, 1 mg/kg
Administration:IP, single
Result:Completely blocked morphine’s antinociceptive effect at 0.5 or 1 mg/kg.
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.
体内研究：
CTAP (0-1 mg/kg, IP, single) blocks morphine’s antinociceptive effect.CTAP (10 mg/kg; IP, single) has no effect on L-DOPA-induced limb, axial, orolingual, or locomotor abnormal involuntary movements.CTAP is stable in the blood and serum of rats (T1/2 > 500 min), showing that the structure of this peptide offers enzymatic resistance. CTAP is extensively protein-bound to albumin in the perfusion medium (68.2%) and to proteins in rat serum (84.2%).Animal Model:Male Sprague-Dawley rats
Dosage:0, 0.1, 0.5, 1 mg/kg
Administration:IP, single
Result:Completely blocked morphine’s antinociceptive effect at 0.5 or 1 mg/kg.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备